A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 127, Issue 1, 2004, Pages 79-86

  Cheng, Davy C H ^a   Mazer, C D ^b   Martineau, R ^c   Ralph Edwards, A ^d   Karski, J ^d   Robblee, J ^e   Finegan, B ^f   Hall, R I ^g   Latimer, R ^h   Vuylsteke, A ^h  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^f UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; HEMOGLOBIN; HEMOGLOBIN RAFFIMER; HETASTARCH; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD PRESSURE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; JAUNDICE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MICTURITION DISORDER; MULTICENTER STUDY; NAUSEA; OXYGEN SATURATION; PAIN; PEROPERATIVE CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; STROKE; SUPRAVENTRICULAR TACHYCARDIA; WOUND INFECTION;

EID: 10744224390     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.08.024     Document Type: Article

References (29)

1. Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DB, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ. 1999;319:16-19.
2. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts - blood transfusion. N Engl J Med. 1999;340:438-47.
3. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 1999;34:1262-347.
4. Graves EJ. National hospital discharge survey: annual summary, 1991. Vital Health Stat 13. 1993;1-62.
5. Stover EP, Siegel LC, Parks R, Levin J, Body SC, Maddi R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology. 1998;88:327-33.
6. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts - blood conservation. N Engl J Med. 1999;340:525-33.
7. Cheng DC. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery. Can J Anaesth. 2001;48: S41-8.
8. Adamson JG, Bonaventura BJ, Er SS, Jones RT, Langlois SF, MacDonald ID, et al. Production, characterization, and clinical evaluation of Hemolink™, an oxidized raffinose cross-linked hemoglobin-based blood substitute. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York: Marcel Dekker Inc; 1997. p. 335-51.
9. Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, Willan AR, et al. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med. 2000;28:2283-92.
10. Higgins TL. Quantifying risk and assessing outcome in cardiac surgery. J Cardiothorac Vasc Anesth. 1998;12:330-40.
11. Grover FL, Shroyer AL, Hammermeister K, Edwards FH, Ferguson TB Jr, Dziuban SW Jr, et al. A decade's experience with quality improvement in cardiac surgery using the Veterans Affairs and Society of Thoracic Surgeons national databases. Ann Surg. 2001;234:464-72; discussion 472-4.
12. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg. 1997;226:501-11; discussion 511-3.
13. Kolvekar S, D'Souza A, Akhtar P, Reek C, Garratt C, Spyt T, et al. Role of atrial ischaemia in development of atrial fibrillation following coronary artery bypass surgery. Eur J Cardiothorac Surg. 1997;11:70-5.
14. Aytemir K, Aksoyek S, Ozer N, Aslamaci S, Oto A. Atrial fibrillation after coronary artery bypass surgery: P wave signal averaged ECG, clinical and angiographic variables in risk assessment. Int J Cardiol. 1999;69:49-56.
15. Borzak S, Tisdale JE, Amin NB, Goldberg AD, Frank D, Padhi ID, et al. Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay? Chest. 1998;113:1489-91.
16. Leslie JB. Incidence and aetiology of perioperative hypertension. Acta Anaesthesiol Scand Suppl. 1993;99:5-9.
17. Malcolm DS, Hamilton IN Jr, Schultz SC, Cole F, Burhop K. Characterization of the hemodynamic response to intravenous diaspirin crosslinked hemoglobin solution in rats. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:91-107.
18. Muldoon SM, Ledvina MA, Hart JL, Macdonald VW. Hemoglobin-induced contraction of pig pulmonary veins. J Lab Clin Med. 1996;128:579-84.
19. Rattan S, Rosenthal GJ, Chakder S. Human recombinant hemoglobin (rHb1.1) inhibits nonadrenergic noncholinergic (NANC) nerve-mediated relaxation of internal anal sphincter. J Pharmacol Exp Ther. 1995;272:1211-6.
20. Cheng DCH, Ralph-Edwards A, Mazer CD, Carmichael FJL, Biro GP. The hemodynamic effects of the red cell substitute Hemolink™ (o-raffinose cross-linked human hemoglobin) on vital signs in patients undergoing CABG surgery [abstract]. Anesthesiology. 2000;93:A180.
21. Alayash AI, Fratantoni JC, Bonaventura C, Bonaventura J, Cashon RE. Nitric oxide binding to human ferrihemoglobins cross-linked between either alpha or beta subunits. Arch Biochem Biophys. 1993;303:332-8.
22. Freas W, Llave R, Jing M, Hart J, McQuillan P, Muldoon S. Contractile effects of diaspirin cross-linked hemoglobin (DCLHb) on isolated porcine blood vessels. J Lab Clin Med. 1995;125:762-7.
23. Schultz SC, Grady B, Cole F, Hamilton I, Burhop K, Malcolm DS. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med. 1993;122:301-8.
24. Ulatowski JA, Nishikawa T, Matheson-Urbaitis B, Bucci E, Traystman RJ, Koehler RC. Regional blood flow alterations after bovine fumaryl beta beta-cross linked hemoglobin transfusion and nitric oxide synthase inhibition. Crit Care Med. 1996;24:558-65.
25. Gulati A, Rebello S. Diaspirin cross-linked hemoglobin (DCLHB): involvement of adrenergic mechanisms in the pressor effect. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:603-12.
26. Hill SE. Oxygen therapeutics - current concepts. Can J Anaesth. 2001;48:S32-40.
27. Jain U. Myocardial infarction during coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 1992;6:612-23.
28. Jain U, Laflamme CJ, Aggarwal A, Ramsay JG, Comunale ME, Ghoshal S, et al. Electrocardiographic and hemodynamic changes and their association with myocardial infarction during coronary artery bypass surgery. A multicenter study. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Anesthesiology. 1997;86:576-91.
29. Randomised trial of normothermic versus hypothermic coronary bypass surgery. The Warm Heart Investigators. Lancet. 1994;343:559-63.